Summary
The European Parliament Approves the World's First Comprehensive AI Legislation
On March 13, 2024, during its plenary session, the European Parliament approved the Proposal for a Regulation of the European Parliament and of the Council Establishing Harmonised Rules on Artificial Intelligence (AI Act). This approval came after the AI Act was signed by the Committee of Permanent Representatives (Coreper) on February 2, 2024, and received backing from both the Internal Market (IMCO) and the Civil Liberties, Justice, and Home Affairs (LIBE) Committees on February 13, 2024.
The Parliament has stated that the AI Act is pending a final review by legal and linguistic experts and is anticipated to be officially passed before the current legislative term ends, utilizing the correction process known as the corrigendum procedure. Additionally, the AI Act requires formal approval from the Council of the European Union. The legislation will become fully enforceable 24 months after it takes effect, with the following exceptions:
- Prohibitions on certain practices will be effective six months after enactment;
- Implementation of codes of practice will start nine months after enactment;
- Rules for general-purpose AI, including governance, will be implemented 12 months after enactment;
- Requirements for high-risk systems will come into effect 36 months after enactment.
Click here to read the press release
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Navigating Privacy Requirements for Clinical Trials Across Jurisdictions: Focus on China
China’s data protection regulations play a crucial role in clinical trials, requiring sponsors and researchers to comply with multiple laws, including the PIPL, GCP-2020, and cross-border data transfer rules. Unlike other jurisdictions, China imposes strict consent requirements, risk assessments, and regulatory filings, making compliance a key factor when selecting trial locations and managing participant data.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part I
Analyzing the Similarities and Differences Between ICH-GCP and GDPR in Clinical Trials
ICH-GCP and GDPR are vital for clinical trials, setting standards for participant protection and data integrity, with distinct focuses and enforcement approaches.
